BIOCRYST PHARMACEUTICALS INC 8-K

What Happened

• BioCryst Pharmaceuticals, Inc. (BCRX) filed an 8-K on February 26, 2026 (Item 2.02) to announce recent corporate developments and its fourth quarter and full year financial results for the year ended December 31, 2025.
• The company issued a press release dated February 26, 2026 (furnished as Exhibit 99.1) and referenced a conference call and webcast to discuss the results and business update. The filing also furnishes an Inline XBRL cover page data file.

Key Details

• Filing date: February 26, 2026; reporting period: quarter and full year ended December 31, 2025.
• Press release titled “BioCryst Reports Full Year 2025 Financial Results and Provides Business Update” is included as Exhibit 99.1.
• Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure) are the primary items reported in this 8-K.
• Inline XBRL cover page interactive data file is provided with the filing.

Why It Matters

• This 8-K is the company’s official disclosure of its Q4 and full-year 2025 financial results and the accompanying business update—key documents investors use to assess recent performance.
• The press release and webcast are the primary sources for numbers, management commentary, and any guidance; investors should review Exhibit 99.1 and the webcast for detailed revenue, earnings and operational metrics.
• Regulation FD disclosure indicates the company disseminated material information broadly and contemporaneously, reducing the risk of selective disclosure.